Trials / NCT06196827
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
Underway, not enrolling Phase 1 Gene therapy
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
- Treatment
- LX101
- Gene
- RPE65
- Conditions
- Inherited Retinal Dystrophy Associated With RPE65 Mutations
- Ages
- 6 Years to no upper limit
- Enrollment
- 9 participants
- Started
- 2022-07-02
- Main results expected
- 2023-12-06
- Results posted
- Not yet
- Record last updated
- 2026-03-06
What the study is testing
The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.
Where it runs
China (2)
- Beijing Tongren Hospital, Capital Medical University, Beijing
- Shanghai General Hospital, Shanghai